
    
      PRIMARY OBJECTIVES:

      I. To evaluate the safety and toxicity of anti-programmed cell death 1 (PD-1) inhibition
      consolidation therapy after radiation therapy for multiple thoracic malignancies.

      SECONDARY OBJECTIVES:

      I. To assess the efficacy of adjuvant anti-PD-1 antibody immunotherapy after radiotherapy.

      II. To understand the dynamics and interactions of IDO with others immune pathway biomarkers.

      III. To evaluate whether IDO immune status could predict the treatment outcomes of radiation
      and immune combined therapy.
    
  